The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis

Experimental Cell Research

Volumn 253, Issue 1, 1999, Pages 78-87

  Kim, Harold ^a   Muller, William J ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Epidermal growth factor receptor; erbB2; Mammary; Neu; Transgenic; Tumorigenesis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; DEREGULATION; DIMERIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; LIGAND BINDING; METASTASIS; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 0033604516     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4706     Document Type: Article

References (109)

1. Hynes N. E., Stern D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta. 1198:1994;165-184.
2. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: Correlation of relapse and survival with the amplification of the HER2/neu oncogene. Science. 235:1987;177-182.
3. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A., Press M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovaian cancer. Science. 244:1989;707-712.
4. Ross J. S., Fletcher J. A. The HER-2/neu oncogene: Prognostic factor, predictive factor and target for therapy. Semin. Cancer Biol. 9:1999;125-138.
5. Andrulis I. L., Bull S. B., Blackstein M. E., Sutherland D., Mak C., Sidlofsky S., Pritzker K. P., Hartwick R. W., Hanna W., Lickley L., Wilkinson R., Qizilbash A., Ambus U., Lipa M., Weizel H., Katz A., Baida M., Mariz S., Stoik G., Dacamara P., Strongitharm D., Geddie W., McCready D. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J. Clin. Oncol. 16:1998;1340-1349.
6. Plowman G. D., Culouscou J. M., Whitney G. S., Green J. M., Carlton G. W., Foy L., Neubauer M. G., Shoyab M. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA. 90:1993;1746-1750.
7. Lacroix H., Iglehart J. D., Skinner M. A., Kraus M. H. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene. 4:1989;145-151.
8. Kraus M. H., Issing W., Miki T., Popescu N. C., Aaronson S. A. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA. 86:1989;9193-9197.
9. Normanno N., Ciardiello F., Brandt R., Salomon D. S. Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. Breast Cancer Res. Treat. 29:1994;11-27.
10. Salomon D. S., Bianco C., De Santis M. Cripto: A novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. Bioessays. 21:1999;61-70.
11. Kenney N. J., Smith G. H., Maroulakou I. G., Green J. H., Muller W. J., Callahan R., Salomon D. S., Dickson R. B. Detection of amphiregulin and Cripto-1 in mammary tumors from transgenic mice. Mol. Carcinog. 15:1996;44-56.
12. Peles E., Yarden Y. Neu and its ligands: From an oncogene to neural factors. Bioessays. 15:1993;815-824.
13. Karunagaran D., Tzahar E., Beerli R. R., Chen X., Graus-Porta D., Ratzkin B. J., Seger R., Hynes N. E., Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer. EMBO J. 15:1996;254-264.
14. Wada T., Qian X. L., Greene M. I. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell. 61:1990;1339-1347.
15. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., Ratzkin B. J., Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 16:1996;5276-5287.
16. Tzahar E., Levkowitz G., Karunagaran D., Yi L., Peles E., Lavi S., Chang D., Liu N., Yayon A., Wen D. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J. Biol. Chem. 269:1994;25226-25233.
17. Pinkas-Kramarski R., Shelly M., Glathe S., Ratzkin B. J., Yarden Y. Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J. Biol. Chem. 271:1996;19029-19032.
18. Pinkas-Kramarski R., Soussan L., Waterman H., Levkowitz G., Alroy I., Klapper L., Lavi S., Seger R., Ratzkin B. J., Sela M., Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15:1996;2452-2467.
19. Pinkas-Kramarski R., Shelly M., Guarino B. C., Wang L. M., Lyass L., Alroy I., Alimandi M., Kuo A., Moyer J. D., Lavi S., Eisenstein M., Ratzkin B. J., Seger R., Bacus S. S., Pierce J. H., Andrews G. C., Yarden Y., Alamandi M. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol. Cell. Biol. 18:1998;6090-6101.
20. Cohen B. D., Kiener P. A., Green J. M., Foy L., Fell H. P., Zhang K. The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J. Biol. Chem. 271:1996;30897-30903.
21. Kokai Y., Myers J. N., Wada T., Brown V. I., LeVea C. M., Davis J. G., Dobashi K., Greene M. I. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell. 58:1989;287-292.
22. Alimandi M., Romano A., Curia M. C., Muraro R., Fedi P., Aaronson S. A., Di Fiore P. P., Kraus M. H. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene. 10:1995;1813-1821.
23. Prigent S. A., Gullick W. J. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 13:1994;2831-2841.
24. Siegel P. M., Ryan E. D., Cardiff R. D., Muller W. J. Elevated expressions of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer. EMBO J. 18:1999;2149-2164.
25. Graus-Porta D., Beerli R. R., Hynes N. E. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 15:1995;1182-1191.
26. Graus-Porta D., Beerli R. R., Daly J. M., Hynes N. E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1997;1647-1655.
27. Qian X., Dougall W. C., Hellman M. E., Greene M. I. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. Oncogene. 9:1994;1507-1514.
28. Qian X., LeVea C. M., Freeman J. K., Dougall W. C., Greene M. I. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: A mechanism of interreceptor kinase activation and transphosphorylation. Proc. Natl. Acad. Sci. USA. 91:1994;1500-1504.
29. Qian X., O'Rourke D. M., Zhao H., Greene M. I. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein. Oncogene. 13:1996;2149-2157.
30. Spivak-Kroizman T., Rotin D., Pinchasi D., Ullrich A., Schlessinger J., Lax I. Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses. J. Biol. Chem. 267:1992;8056-8063.
31. Wong L., Deb T. B., Thompson S. A., Wells A., Johnson G. R. A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling. J. Biol. Chem. 274:1999;8900-8909.
32. Soltoff S. P., Carraway K. L. III, Prigent S. A., Gullick W. G., Cantley L. C. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol. 14:1994;3550-3558.
33. Wilson L. K., Luttrell D. K., Parsons J. T., Parsons S. J. pp60c-src tyrosine kinase, myristylation, and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-src. Mol. Cell. Biol. 9:1989;1536-1544.
34. Luttrell D. K., Luttrell L. M., Parsons S. J. Augmented mitogenic responsiveness to epidermal growth factor in murine fibroblasts that overexpress pp60c-src. Mol. Cell. Biol. 8:1988;497-501.
35. Osherov N., Levitzki A. Epidermal-growth-factor-dependent activation of the src-family kinases. Eur. J. Biochem. 225:1994;1047-1053.
36. Sato K., Sato A., Aoto M., Fukami Y. c-Src phosphorylates epidermal growth factor receptor on tyrosine 845. Biochem. Biophys. Res. Commun. 215:1995;1078-1087.
37. Maa M. C., Leu T. H., McCarley D. J., Schatzman R. C., Parsons S. J. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: Implications for the etiology of multiple human cancers. Proc. Natl. Acad. Sci. USA. 92:1995;6981-6985.
38. Tice D. A., Biscardi J. S., Nickles A. L., Parsons S. J. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA. 96:1999;1415-1420.
39. Biscardi J. S., Maa M. C., Tice D. A., Cox M. E., Leu T. H., Parsons S. J. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem. 274:1999;8335-8343.
40. Muthuswamy S. K., Muller W. J. Activation of the Src family of tyrosine kinases in mammary tumorigenesis. Adv. Cancer Res. 64:1994;111-123.
41. Muthuswamy S. K., Muller W. J. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene. 11:1995;271-279.
42. Muthuswamy S. K., Muller W. J. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. Oncogene. 11:1995;1801-1810.
43. Olayioye M. A., Beuvink I., Horsch K., Daly J. M., Hynes N. E. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J. Biol. Chem. 274:1999;17209-17218.
44. Olayioye M. A., Graus-Porta D., Beerli R. R., Rohrer J., Gay B., Hynes N. E. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol. Cell. Biol. 18:1998;5042-5051.
45. Burden S., Yarden Y. Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis. Neuron. 18:1997;847-855.
46. DiGiovanna M. P., Lerman M. A., Coffey R. J., Muller W. J., Cardiff R. D., Stern D. F. Active signaling by Neu in transgenic mice. Oncogene. 17:1998;1877-1884.
47. Arteaga C. L., Dugger T. C., Hurd S. D. The multifunctional role of transforming growth factor (TGF)-beta s on mammary epithelial cell biology. Breast Cancer Res. Treat. 38:1996;49-56.
48. Jhappan C., Stahle C., Harkins R. N., Fausto N., Smith G. H., Merlino G. T. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell. 61:1990;1137-1146.
49. Matsui Y., Halter S. A., Holt J. T., Hogan B. L., Coffey R. J. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell. 61:1990;1147-1155.
50. Sandgren E. P., Luetteke N. C., Palmiter R. D., Brinster R. L., Lee D. C. Overexpression of TGF alpha in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell. 61:1990;1121-1135.
51. Sandgren E. P., Schroeder J. A., Qui T. H., Palmiter R. D., Brinster R. L., Lee D. C. Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res. 55:1995;3915-3927.
52. Muller W. J., Arteaga C. L., Muthuswamy S. K., Siegel P. M., Webster M. A., Cardiff R. D., Meise K. S., Li F., Halter S. A., Coffey R. J. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol. Cell. Biol. 16:1996;5726-5736.
53. Amundadottir L. T., Nass S. J., Berchem G. J., Johnson M. D., Dickson R. B. Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: Coordinated stimulation of growth and suppression of apoptosis. Oncogene. 13:1996;757-765.
54. Escot C., Theillet C., Lidereau R., Spyratos F., Champeme M. H., Gest J., Callahan R. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc. Natl. Acad. Sci. USA. 83:1986;4834-4838.
55. Luetteke N. C., Qiu T. H., Fenton S. E., Troyer K. L., Riedel R. F., Chang A., Lee D. C. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development. 126:1999;2739-2750.
56. Luetteke N. C., Phillips H. K., Qiu T. H., Copeland N. G., Earp H. S., Jenkins N. A., Lee D. C. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev. 8:1994;399-413.
57. Fowler K. J., Walker F., Alexander W., Hibbs M. L., Nice E. C., Bohmer R. M., Mann G. B., Thumwood C., Maglitto R., Danks J. A. A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. Proc. Natl. Acad. Sci. USA. 92:1995;1465-1469.
58. Guy C. T., Cardiff R. D., Muller W. J. Activated neu induces rapid tumor progression. J. Biol. Chem. 271:1996;7673-7678.
59. Muller W. J., Sinn E., Pattengale P. K., Wallace R., Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 54:1988;105-115.
60. Lucchini F., Sacco M. G., Hu N., Villa A., Brown J., Cesano L., Mangiarini L., Rindi G., Kindl S., Sessa F. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. Cancer Lett. 64:1992;203-209.
61. Bouchard L., Lamarre L., Tremblay P. J., Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell. 57:1989;931-936.
62. Rowse G. J., Ritland S. R., Gendler S. J. Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis. Cancer Res. 58:1998;2675-2679.
63. Thompson J. A., Eades-Perner A. M., Ditter M., Muller W. J., Zimmermann W. Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: An animal model for CEA-directed tumor immunotherapy. Int. J. Cancer. 72:1997;197-202.
64. Wang B., Kennan W. S., Yasukawa-Barnes J., Lindstrom M. J., Gould M. N. Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains. Cancer Res. 51:1991;5649-5654.
65. Tai Y. T., Gould M. N. The genetic penetrance of the activated neu oncogene for the induction of mammary cancer in vivo. Oncogene. 14:1997;2701-2707.
66. Tai Y. T., Gould M. N. Hormonal modulation of neu-induced mammary carcinogenesis: Evidence against a single-step induction of mammary cancer by neu. Carcinogenesis. 16:1995;1455-1459.
67. Cool M., Jolicoeur P. Elevated frequency of loss of heterozygosity in mammary tumors arising in mouse mammary tumor virus/neu transgenic mice. Cancer Res. 59:1999;2438-2444.
68. Lemoine N. R., Staddon S., Dickson C., Barnes D. M., Gullick W. J. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene. 5:1990;237-239.
69. Guy C. T., Webster M. A., Schaller M., Parsons T. J., Cardiff R. D., Muller W. J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA. 89:1992;10578-10582.
70. Siegel P. M., Dankort D. L., Hardy W. R., Muller W. J. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol. 14:1994;7068-7077.
71. Siegel P. M., Muller W. J. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Proc. Natl. Acad. Sci. USA. 93:1996;8878-8883.
72. Dankort D. L., Wang Z., Blackmore V., Moran M. F., Muller W. J. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol. Cell. Biol. 17:1997;5410-5425.
73. Hemmings B. A. Akt signaling: Linking membrane events to life and death decisions. Science. 275:1997;628-630.
74. Webster M. A., Hutchinson J. N., Rauh M. J., Muthuswamy S. K., Anton M., Tortorice C. G., Cardiff R. D., Graham F. L., Hassell J. A., Muller W. J. Requirement for both Shc and phosphatidylinositol 3′ kinase signaling pathways in Polyomavirus middle T-mediated mammary tumorigenesis. Mol. Cell. Biol. 18:1998;2344-2359.
75. Krane I. M., Leder P. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene. 12:1996;1781-1788.
76. Kwong K. Y., Hung M. C. A novel splice variant of HER2 with increased transformation activity. Mol. Carcinog. 23:1998;62-68.
77. Amundadottir L. T., Leder P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene. 16:1998;737-746.
78. Muthuswamy S. K., Siegel P. M., Dankort D. L., Webster M. A., Muller W. J. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol. Cell. Biol. 14:1994;735-743.
79. Guy C. T., Muthuswamy S. K., Cardiff R. D., Soriano P., Muller W. J. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev. 8:1994;23-32.
80. Ritland S. R., Rowse G. J., Chang Y., Gendler S. J. Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. Cancer Res. 57:1997;3520-3525.
81. Callahan R., Cropp C. S., Merlo G. R., Liscia D. S., Cappa A. P., Lidereau R. Somatic mutations and human breast cancer. A status report. Cancer. 69:1992;1582-1588.
82. Chen L. C., Neubauer A., Kurisu W., Waldman F. M., Ljung B. M., Goodson W. d., Goldman E. S., Moore D. d., Balazs M., Liu E. Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc. Natl. Acad. Sci. USA. 88:1991;3847-3851.
83. Singh S., Simon M., Meybohm I., Jantke I., Jonat W., Maass H., Goedde H. W. Human breast cancer: Frequent p53 allele loss and protein overexpression. Hum. Genet. 90:1993;635-640.
84. Li B., Rosen J. M., McMenamin-Balano J., Muller W. J., Perkins A. S. neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol. Cell. Biol. 17:1997;3155-3163.
85. Rudolph-Owen L. A., Chan R., Muller W. J., Matrisian L. M. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res. 58:1998;5500-5506.
86. Donehower L. A., Harvey M., Slagle B. L., McArthur M. J., Montgomery C. A. Jr., Butel J. S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221.
87. Threadgill D. W., Dlugosz A. A., Hansen L. A., Tennenbaum T., Lichti U., Yee D., LaMantia C., Mourton T., Herrup K., Harris R. C. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science. 269:1995;230-234.
88. Sibilia M., Wagner E. F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science. 269:1995;234-238.
89. Lee K. F., Simon H., Chen H., Bates B., Hung M. C., Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 378:1995;394-398.
90. Riethmacher D., Sonnenberg-Riethmacher E., Brinkmann V., Yamaai T., Lewin G. R., Birchmeier C. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature. 389:1997;725-730.
91. Sauer B., Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc. Natl. Acad. Sci. USA. 85:1988;5166-5170.
92. Wagner K. U., Wall R. J., St-Onge L., Gruss P., Wynshaw-Boris A., Garrett L., Li M., Furth P. A., Hennighausen L. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res. 25:1997;4323-4330.
93. Hamilton D. L., Abremski K. Site-specific recombination by the bacteriophage P1 lox-Cre system. Cre-mediated synapsis of two lox sites. J. Mol. Biol. 178:1984;481-486.
94. Xu X., Wagner K. U., Larson D., Weaver Z., Li C., Ried T., Hennighausen L., Wynshaw-Boris A., Deng C. X. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. 22:1999;37-43.
95. Hennighausen L., Robinson G. W. Think globally, act locally: The making of a mouse mammary gland. Genes Dev. 12:1998;449-455.
96. Houston S. J., Plunkett T. A., Barnes D. M., Smith P., Rubens R. D., Miles D. W. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br. J. Cancer. 79:1999;1220-1226.
97. De Placido S., Carlomagno C., De Laurentiis M., Bianco A. R. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. Breast Cancer Res. Treat. 52:1998;55-64.
98. Newby J. C., Johnston S. R., Smith I. E., Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin. Cancer Res. 3:1997;1643-1651.
99. Carlomagno C., Perrone F., Gallo C., De Laurentiis M., Lauria R., Morabito A., Pettinato G., Panico L., D'Antonio A., Bianco A. R., De Placido S. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol. 14:1996;2702-2708.
100. Dankort D. L., Muller W. J. Transgenic models of breast cancer metastasis. Cancer Treat. Res. 83:1996;71-88.
101. Sternlicht M. D., Lochter A., Sympson C. J., Huey B., Rougier J. P., Gray J. W., Pinkel D., Bissell M. J., Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 98:1999;137-146.
102. Thomasset N., Lochter A., Sympson C. J., Lund L. R., Williams D. R., Behrendtsen O., Werb Z., Bissell M. J. Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. Am. J. Pathol. 153:1998;457-467.
103. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N. P., Risau W., Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 72:1993;835-846.
104. Millauer B., Longhi M. P., Plate K. H., Shawver L. K., Risau W., Ullrich A., Strawn L. M. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56:1996;1615-1620.
105. Fukumura D., Xavier R., Sugiura T., Chen Y., Park E. C., Lu N., Selig M., Nielsen G., Taksir T., Jain R. K., Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell. 94:1998;715-725.
106. Drebin J. A., Link V. C., Stern D. F., Weinberg R. A., Greene M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell. 41:1985;697-706.
107. Hudziak R. M., Lewis G. D., Winget M., Fendly B. M., Shepard H. M., Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9:1989;1165-1172.
108. Klapper L. N., Glathe S., Vaisman N., Hynes N. E., Andrews G. C., Sela M., Yarden Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl. Acad. Sci. USA. 96:1999;4995-5000.
109. Cox A. D., Der C. J. Biochim. Biophys. Acta. 1333:1997;F51-F71.